Biological Rationale Explained for Continued Investigation of Immunotherapy in Sarcomas – Targeted Oncology
Targeted Oncology |
Biological Rationale Explained for Continued Investigation of Immunotherapy in Sarcomas
Targeted Oncology Combination approaches with immunotherapy are increasingly being investigated in studies of patients with sarcoma. Tap first pointed to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic sarco- mas. Patients … |
